Longboard Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference on September 28, 2021
September 21 2021 - 8:30AM
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a
clinical-stage biopharmaceutical company focused on developing
novel, transformative medicines for neurological diseases, today
announced that members of its senior leadership team will present
in a fireside chat format at the Cantor Virtual Global Healthcare
Conference on September 28, 2021.
Presentation Details:
Cantor Global Healthcare Conference: Tuesday,
September 28, 2021, at 11:20 AM ET (Track 4)
To access a live webcast of Longboard’s
presentation, please visit the “Events & Presentations” page
within the Investors Relations section of Longboard’s website at
https://ir.longboardpharma.com/. A replay of the webcast will be
available shortly after the completion of the event and archived on
the website for at least 30 days.
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard was
formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to
advance a portfolio of centrally acting product candidates designed
to be highly selective for specific G protein-coupled receptors
(GPCRs). Longboard’s small molecule product candidates were
discovered out of the same platform at Arena that represents a
culmination of more than 20 years of GPCR research. Longboard is
evaluating LP352, an oral, centrally acting, next-generation
5-hydroxytryptamine 2c receptor superagonist, with negligible
observed impact on 5-HT2b and 5-HT2a receptor subtypes, in
development for the potential treatment of seizures associated with
developmental and epileptic encephalopathies. Longboard is also
evaluating LP143, a centrally acting, full cannabinoid type 2
receptor agonist, in development for the potential treatment of
neurodegenerative diseases associated with neuroinflammation caused
by microglial activation, and LP659, a centrally acting,
sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in
development for the potential treatment of central nervous system
neuroinflammatory diseases.
Forward-Looking
StatementsCertain statements in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Such forward-looking statements include statements
about Longboard’s participation in the upcoming conference,
clinical and preclinical programs, ability to develop medicines,
and focus. For such statements, Longboard claims the protection of
the Private Securities Litigation Reform Act of 1995. Actual events
or results may differ materially from Longboard’s expectations.
Factors that could cause actual results to differ materially from
those stated or implied by Longboard’s forward-looking statements
are disclosed in Longboard’s filings with the Securities and
Exchange Commission (SEC). These forward-looking statements
represent Longboard’s judgment as of the time of this release.
Longboard disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate Contact:
Megan E. Knight
Head of Investor Relations
mknight@longboardpharma.com
IR@longboardpharma.com
619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024